Étude multicentrique, contrôlée avec placebo, randomisée, en double aveugle, destinée à évaluer l'efficacité et la sécurité d'emploi d'un émdicament à l'étude appelé "'omécamtiv mécarbil" sur la mortalité et la morbidité chez des sujets souffrant d'insuffisance cardiaque chronique avec réduction de la fraction d'éjection

Drug: Omecamtiv Mecarbil;Drug: Placebo;Drug: Standard of Care

Key Inclusion Criteria:

- Subject has provided informed consent

- Male or female, = 18 to = 85 years

- History of chronic heart failure (HF), defined as requiring treatment for HF for a
minimum of 30 days before randomization

- Left ventricle ejection fraction (LVEF) = 35%, per subjects most recent medical
record, within 12 months prior to screening.

- New York Heart Association (NYHA) class II to IV at most recent screening assessment.

- Managed with HF standard of care (SoC) therapies consistent with regional clinical
practice guidelines according to investigator judgment of subject's clinical status

- Current hospitalization with primary reason of HF OR one of the following events
within 1 year of screening: hospitalization with primary reason of HF; urgent visit to
emergency department (ED) with primary reason of HF.

- Elevated B-type natriuretic peptide (BNP) or n-terminal-prohormone brain natriuretic
peptide (NT-proBNP)

Other Inclusion Criteria May apply

Key Exclusion Criteria:

- Currently receiving treatment in another investigational device or drug study, or < 30
days since ending treatment on another investigational device or drug study(ies).
Other investigational procedures while participating in this study are excluded.

- Malignancy within 5 years prior to randomization with the following exceptions:
localized basal or squamous cell carcinoma of the skin, cervical intraepithelial
neoplasia, stage 1 prostate carcinoma, breast ductal carcinoma in situ.

- Subject has known sensitivity to any of the products or components to be administered
during testing

Other Exclusion Criteria May apply